Volume 31, Number 2—February 2025
Research
Contribution of Limited Molecular Testing to Low Ehrlichiosis Diagnosis in High Incidence Area, North Carolina, USA
Alexis Siegler, Lauryn Ursery, Dana A. Giandomenico, Melissa B. Miller, Johanna S. Salzer, Alexis M. Barbarin, Carl Williams, and Ross M. Boyce
Table 1
Clinical symptoms among patients tested for tickborne disease at a visit within the University of North Carolina health system, March 24, 2022–April 14, 2023
| Clinical symptoms | No. (%) patients |
|---|---|
| Meets clinical criteria | 273 (28.9) |
| Fever and headache | 151 (55.3) |
| Fever and myalgia | 152 (55.7) |
| Fever and anemia | 92 (33.7) |
| Fever and thrombocytopenia* | 65 (23.8) |
| Fever and hepatic transaminase elevation† | 78 (28.6) |
| Fever and leukopenia‡ | 42 (15.4) |
| Tick bite noticed in previous 2 weeks |
77 (28.3) |
| Does not meet clinical criteria | 672 (71.1) |
| Fever | 14 (2.1) |
| Headache | 145 (21.6) |
| Myalgia | 168 (25) |
| Anemia | 50 (7.3) |
| Thrombocytopenia | 28 (4.2) |
| Hepatic transaminase elevation | 47 (7) |
| Leukopenia | 26 (3.9) |
| Bite noticed in 2 weeks prior | 205 (30.5) |
| No symptoms or bite noticed | 69 (10.3) |
*Platelets <150,000/μL. †Aspartate aminotransferase >33 U/L or alanine aminotransferase >36 U/L. ‡Leukocytes <4,000 cells/μL.
Page created: January 13, 2025
Page updated: January 31, 2025
Page reviewed: January 31, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.